AEON Biopharma, Inc. AEON

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

AEON is a biopharmaceutical company advancing its proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) with the goal of achieving full-label United States ("U.S.") market entry for debilitating medical conditions.

On December 12, 2022, AEON Biopharma Sub, Inc. (formerly known as AEON Biopharma, Inc.) ("Old AEON") and Priveterra Merger Sub, Inc., a wholly owned subsidiary of Priveterra Acquisition Corp. ("Priveterra"), a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more target businesses, entered into a Business Combination and Merger Agreement (the "Business Combination Agreement" or "BCA") dated December 12, 2022 and amended April 27, 2023.

Last close 0.24 2026-10-23
Market cap $12.0M 2026-06-30 share count
52-week range 0.18 - 1.45

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.95

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
R&D $4.1M$14.2M—$34.8M——
SG&A $12.2M$13.6M—$13.7M——
Total operating expenses $12.8M-$73.0M—$48.4M——
Operating income -$12.8M$73.0M—-$48.4M-$1.9M—
Pre-tax income -$39.2M$42.0M—-$52.6M$8.2M—
Income tax $0$0—$0——
Net income -$39.2M$42.0M—-$52.6M$8.2M—
EPS, basic -3.9577.74—-0.38——
EPS, diluted -3.9572.93—-0.38——
Shares, diluted (wtd. avg.) 9.9M575,945—138.8M——

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents $3.0M$13.0K$5.2M$9.7M$5.1M—
Total current assets $3.4M$1.6M$6.2M$9.8M$835.2K—
Property, plant and equipment $162.0K$235.0K$332.0K$431.0K——
Total assets $5.6M$3.1M$6.8M$10.8M$276.9M$81.0K
Accounts payable $942.0K$5.9M$3.4M$7.8M$634.6K$21.0K
Total current liabilities $6.9M$14.1M$13.0M$82.6M$834.6K$59.6K
Total liabilities $60.6M$31.7M$159.9M$143.2M$17.9M$59.6K
Retained earnings -$470.8M-$431.6M-$473.6M-$474.8M-$17.0M-$3.6K
Total equity -$55.0M-$28.6M-$153.0M-$270.4M-$223.8M$21.4K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Operating cash flow -$17.3M-$20.3M—-$35.6M-$1.5M—
Depreciation and amortisation $78.0K$97.0K—$68.0K——
Stock-based compensation $5.3M$6.2M—$5.9M——
Capital expenditure $4.0K——$306.0K——
Investing cash flow -$4.0K——-$306.0K-$276.0M—
Financing cash flow $20.3M$15.1M—$40.5M$278.0M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001837607-26-000019.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -75M -50M -25M 0 25M 50M Net income, FY2021: 8.2M Net income, FY2022: -52.6M Net income, FY2024: 42M Net income, FY2025: -39.2M FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — —
Gross profit — — — — — —
Net income — $8.2M -$52.6M — $42.0M -$39.2M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Regulation FD disclosure Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%